CTOs on the Move

Vigil Neuroscience

www.vigilneuro.com

 
Vigil Neuroscience is the world`s first microglia-focused therapeutics company. Our purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain`s immune system. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.vigilneuro.com
  • One Broadway Suite 07-300
    Cambridge, MA USA 02142
  • Phone: 857.254.4445

Executives

Name Title Contact Details

Funding

Vigil Neuroscience raised $50M on 12/08/2020

Similar Companies

Haichang

Zhejiang Haichang is a biopharmaceutical company based in Hangzhou, China. They specialize in the development of mRNA vaccines, nucleic acid drug delivery, and lipid nanoparticle technologies.

Walgreens

At Walgreens, we help people get, stay and live well. That`s our core purpose and the difference we make in people`s lives every day. Our purpose has shaped the direction of our company since Charles R. Walgreen Sr. founded his first drugstore in 1901, and it still does today. Our team members make that purpose come to life in our over 7,800 stores in all 50 states, the District of Columbia and Puerto Rico, in our call centers, distribution centers, on-site clinics, specialty pharmacies and corporate offices. In fact, those daily demonstrations of our purpose have helped Walgreens become an industry leader and a household name. Walgreens has something for everyone who wants to build a successful career. Here, you`ll find supportive co-workers, an innovative environment and the tools you need to grow your skills, help build healthy communities and advance your career.

EPIC Behavioral Healthcare

...your behavioral health specialty care provider

BVI

Beaver-Visitec International (BVI) is a highly regarded ophthalmic device manufacturer offering a broad range of single use instruments & custom procedure packs

ProNAi

ProNAi Therapeutics is a clinical-stage oncology company pioneering a novel class of therapeutics based on its proprietary DNAi technology platform for patients with cancer and hematological diseases. ProNAi`s lead DNAi product candidate, PNT2258, is designed to treat cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is pursuing a multi-faceted clinical development strategy designed to efficiently achieve regulatory approval and maximize the commercial opportunity of PNT2258. ProNAi recently initiated "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma.